Genta (company)

Genta, Inc.
Traded as OTCQB: GNTA
Industry Biotechnology
Headquarters Berkeley Heights, New Jersey

Genta Inc. was a biopharmaceutical company based in Berkeley Heights, New Jersey, United States, which develops products for the treatment of patients with cancer. In August 2012 the company filed for bankruptcy.


Its products include:

Financial record

In addition to financing agreements with institutional investors, through its history, Genta Inc., like most listed unprofitable development stage start ups, has made reverse stock splits and stock dilution in order to get financial resources and stay afloat. For example, in July 2009, the company implemented a reverse stock split, which replaced 50 old shares with one new share.[2]

On July 9, 2008, The NASDAQ Stock Market(r) announced that it will delist the common stock of Genta Incorporated. Genta Incorporated's stock was suspended on May 6, 2008 and has not traded on NASDAQ(r) since that time. NASDAQ will file a Form 25 with the Securities and Exchange Commission to complete the delisting. The delisting becomes effective ten days after the Form 25 is filed.

Currently, Genta stock is trading on the OTC Pink Sheets


  1. Feuerstein, Adam (October 29, 2009). "Genta Melanoma Drug Study Disappoints: BioBuzz". Retrieved 10 January 2010.
  2. "Genta Implements Reverse Stock Split New Trading Symbol is "GETA"". Press Release. Genta Inc. July 13, 2009. Retrieved 10 January 2010.

External links

Official website

Coordinates: 40°39′50″N 74°24′53″W / 40.6638°N 74.4148°W / 40.6638; -74.4148

This article is issued from Wikipedia - version of the 4/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.